Model Development and Prospective Validation to Predict the Response to Neoadjuvant Chemotherapy in Cervical Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01628757|
Recruitment Status : Recruiting
First Posted : June 27, 2012
Last Update Posted : May 17, 2016
Cervical cancer is one of the major health problems for chinese women. Besides surgery and radiotherapy, neoadjuvant chemotherapy has been proved to be an effective program by many studies.
However, not all patients respond well to neoadjuvant chemotherapy. Knowing the therapeutic effect of the neoadjuvant chemotherapy before receiving it can not only reduce the economic burden, but also more importantly save time to take more suitable treatments.
This study is undertaken to build a model combine both clinical and genetic factors to predict the effects of neoadjuvant chemotherapy.
|Condition or disease|
Show Detailed Description
|Study Type :||Observational|
|Estimated Enrollment :||1400 participants|
|Official Title:||Model Development and Prospective Validation to Predict the Response to Neoadjuvant Chemotherapy in Cervical Cancer|
|Estimated Primary Completion Date :||December 2018|
|Estimated Study Completion Date :||December 2023|
- The clinical and pathological response to neoadjuvant chemotherapy [ Time Frame: 1 to 3 months ]including: ① clinical response（tumor size）, ②pathological response（<3 mm or not）, ③toxic response (degree) and so on.
- long-term response for patients undergoing neoadjuvant chemotherapy [ Time Frame: up to 10 years to 20 years or more ]including ① DFS, ②OS, ③long-term complications，④secondary diseases, ⑤life quality, ⑥long-term toxic effects caused by the treatment and so on.
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01628757
|Contact: Ma Ding, M.D.||firstname.lastname@example.org|
|Wuhan, Hubei, China, 430030|
|Contact: Ma Ding, M.D. 86-27-8362681 email@example.com|